Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Palisade Bio presented clinical and translational data for PALI-2108 at UEG Week 2026, highlighting a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in fecal calprotectin after 14 days in a five-patient fibrostenotic Crohn's disease cohort. A separate five-patient ulcerative colitis cohort showed clinical response in all five patients at Day 7, and tissue analyses demonstrated intestinal exposure of the active metabolite roughly 7.3-fold above peak plasma levels, supporting once-daily oral dosing. The company is enrolling the Phase 2b ASCENTRA-UC study in approximately 204 patients and initiating a Phase 2a Crohn's disease study.
Key figures
- Drug Name
- PALI-2108
- Phase Of Trial
- Phase 1b / Phase 2b
- Fscd cohort size
- 5
- Uc clinical response
- 5 of 5 patients
- Fecal calprotectin reduction
- 58.8%
- Ascentra uc enrollment target
- 204
- Endoscopic activity reduction
- 47.5%
- Tissue to plasma exposure ratio
- 7.3-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.